Statements (31)
Predicate | Object |
---|---|
gptkbp:instanceOf |
gptkb:drug
|
gptkbp:approvalYear |
2018
|
gptkbp:approvedBy |
gptkb:FDA
|
gptkbp:ATCCode |
L01XC32
|
gptkbp:brand |
gptkb:Poteligeo
|
gptkbp:CASNumber |
1008201-43-6
|
gptkbp:developer |
gptkb:Kyowa_Kirin
|
gptkbp:form |
solution for infusion
|
gptkbp:genericName |
mogamulizumab
|
https://www.w3.org/2000/01/rdf-schema#label |
Poteligeo
|
gptkbp:indication |
leukemia
relapsed or refractory Sézary syndrome relapsed or refractory mycosis fungoides |
gptkbp:legalStatus |
prescription only
|
gptkbp:macromoleculeType |
gptkb:monoclonal_antibody
|
gptkbp:mechanismOfAction |
anti-CCR4 monoclonal antibody
|
gptkbp:PregnancyCategory |
not assigned
|
gptkbp:routeOfAdministration |
intravenous
|
gptkbp:sideEffect |
diarrhea
fatigue infections rash musculoskeletal pain infusion reaction |
gptkbp:target |
gptkb:CCR4
|
gptkbp:UNII |
6QY1D43K5B
|
gptkbp:usedFor |
gptkb:mycosis_fungoides
gptkb:Sézary_syndrome |
gptkbp:bfsParent |
gptkb:Kyowa_Kirin
gptkb:Kyowa_Hakko_Kirin |
gptkbp:bfsLayer |
7
|